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ABSTRACT
CrossFit athletes are frequently subjected to high-intensity training sessions that demand commensurately
robust muscular and cardiovascular endurance capacities. Despite the propensity of research investigating
the role of aerobically-associated ergogenic aids, few have elucidated their combination in highly trained
athletic populations. PURPOSE: to evaluate the preliminary efficacy of a novel supplement comprising
several empirically-supported ingredients and their potential ability to impact the aerobic performance in
experienced CrossFit athletes. METHODS: Six experienced CrossFit athletes (3M/3F; aged 4113y; training
51 times/week) ingested 2.0mL daily of a novel supplement proprietary formulation (Flow, Cerus, Vero
Bleach, FL) containing Beetroot (Beta Vulgaris), Ashwagandha (Withania Somnifera), Arjuna (Terminalia
Arjuna), Rhodiola (Rhodiola Rosea), as well as Cayenne (Capsicum Annuum) for 28 days between a
baseline and post-supplementation maximal oxygen consumption (VO2MAX) assessment. Participants were
asked not to change their exercise habits and consumed the aforementioned supplement 30 minutes prior
to each training session and/or during the morning on rest days. A 4.0mL supplement dose was additionally
administered 30 minutes prior to the post-supplementation aerobic capacity assessment. Both the treadmill
VO2MAX and test time-to-fatigue (elapsed finish-start time) were analyzed using separate paired-samples ttests at a significance level of p<.05. RESULTS: Although VO2MAX did not significantly increase (p=.146;
Hedge’s G=.737), the participants’ treadmill assessment TTE demonstrated a statistically significant
improvement (p=.012, Hedge’s G=.726) from pre- to post-supplementation (10.67 to 12.11 minutes
[13.55%], respectively). Notably, the 2/6 participants that experienced pre- to post-supplementation VO2MAX
decrements tested positive for COVID-19 during their supplementation period. CONCLUSION: The present
pilot study showcases the potential of a novel aerobically-associated ergogenic supplement. Nevertheless,
future research should more rigorously evaluate these data by employing a randomized, double-blinded,
and placebo-controlled design, as well as a larger sample size before any definitive conclusions may be
inferred.
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